Compare Futu Holdings Ltd (FUTU) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Viatris Inc — how do they compare? Futu Holdings Ltd trades at $98.17 (market cap $13.94B), while Viatris Inc trades at $17.22 (market cap $19.44B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| FUTU | VTRS | |
|---|---|---|
Market Cap | $13.94B | $19.44B |
Sector | Financials | Health |
52-Week High | $199.04 | $17.39 |
52-Week Low | $89.76 | $8.74 |
Enterprise Value | $13.79B | $31.65B |
Dividend Yield | 2.62% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUTU trades at $98.2, up 0.07% on the day, with a bullish technical signal but mixed earnings history including a Q1 2026 miss. The company shows strong fundamentals with 2025 revenue of $22.85B, net income margin of 49.62%, and robust cash flow. However, multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The outlook is clouded by legal risks despite solid profitability and analyst support (58% buy ratings). Investment opportunity hinges on resolution of regulatory allegations, while key risks include potential financial penalties and reputational damage from ongoing litigation.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
